Literature DB >> 34339261

Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation.

Jens Köhler1, Pasi A Jänne1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34339261     DOI： 10.1200/JCO.21.01494

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Molecular targeted therapy for anticancer treatment.

Authors:  Hye-Young Min; Ho-Young Lee
Journal:  Exp Mol Med       Date:  2022-10-12       Impact factor: 12.153

2.  Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma.

Authors:  Lingling Zhu; Yanyang Liu; Honglin Gao; Jiewei Liu; Qinghua Zhou; Feng Luo
Journal:  Front Cell Dev Biol       Date:  2022-01-10

3.  Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation.

Authors:  Boning Cai; Xiaomo Li; Xiang Huang; Tonghui Ma; Baolin Qu; Wei Yu; Wei Yang; Pei Zhang; Jing Chen; Fang Liu
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

Review 4.  EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives.

Authors:  Jiabao Hou; Hongle Li; Shuxiang Ma; Zhen He; Sen Yang; Lidan Hao; Hanqiong Zhou; Zhe Zhang; Jing Han; Li Wang; Qiming Wang
Journal:  Biomark Res       Date:  2022-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.